AD subgroups, based on the distribution of tau pathology and corresponding brain atrophy have also been identified by many neuroimaging studies using structural magnetic resonance imaging (MRI) and tau-positron emission tomography (PET) [23,24,25,26]. This evidence concerns the gene MAPT and Alzheimer disease.